Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer

NCT01901146 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01901146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01901146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
April 29, 2013
Completion date
January 27, 2017
Enrollment
725 (actual)
Sites
98

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer